Cipla

1,458.20

+2.20

(0.15%)

Market Cap

1,17,800.00 Cr

PE Ratio

30.47

Volume

12,61,674.00

Day High - Low

1,471.00 - 1,452.00

52W High-Low

1,673.00 - 1,165.70

compare with

Sun Pharmaceutical

1,904.80 (+1.81%)

Divis Laboratories

6,757.00 (+1.11%)

Torrent Pharmaceuticals

4,768.30 (+2.29%)

Zydus Life Science

1,140.60 (+3.71%)

Dr Reddys Laboratories

1,374.10 (+2.11%)

Key Fundamentals

Market Cap

1,17,800.00 Cr

EPS

48.03

PE Ratio

30.47

PB Ratio

3.42

Book Value

426.22

EBITDA

6,764.90

Dividend Yield

0.89 %

Industry

Healthcare

Sector

Pharmaceuticals

Return on Equity

11.21

Debt to Equity

0.02

Actual

Company News

View All News

Cipla reports highest ever revenue of ₹28,000 crore

18 hrs ago

Cipla recorded its highest ever revenue of ₹28,000 crore for FY26 with a 21% EBITDA margin. The Board recommended a final dividend of ₹30 per share.

Cipla to Consider Q1 Results on July 232 days ago

Cipla has announced that its board will meet on July 23 to consider the company's financial results for the first quarter.

Cipla Block Trade: Rs. 25.83 Cr Deal on NSE4 days ago

Cipla sees a block trade of ~1,76,199 shares on NSE, valued at Rs. 25.83 crores at a price of Rs. 1466.00 per share.

Peer Comparison Compare Peers on Screener

Competitors	LTP	Market Cap (₹ Cr.)	P/E Ratio	Revenue (₹ Cr.)	YoY Revenue Growth %	Net Profit (₹ Cr.)	YoY Profit Growth %	RSI
Sun Pharmaceutical	1,904.80	#1 4,57,025.33	39.02	#1 58,220.10	6.38	#1 11,565	25.80	69.58
Divis Laboratories	6,757.00	1,79,377.12	69.00	10,560.00	8.73	2,520	13.44	55.41
Torrent Pharmaceuticals	4,768.30	1,61,380.94	73.80	13,886.20	20.34	2,138	-26.91	70.39
Cipla	1,458.20	#4 1,17,800.00	#5 30.47	#4 29,044.60	#9 2.24	#5 3,870	#9 -55.32	66.80
Zydus Life Science	1,140.60	1,14,771.05	21.60	26,719.70	13.65	5,242	7.82	66.88
Dr Reddys Laboratories	1,374.10	1,14,691.88	27.03	33,593.30	-0.44	3,998	-86.05	67.04
Lupin	2,476.00	1,13,210.78	#1 20.48	27,487.50	19.98	5,345	#1 87.72	71.73
Mankind Pharma	2,528.60	1,04,430.16	53.00	14,277.60	12.03	1,750	31.75	60.79
Aurobindo Pharma	1,620.50	93,239.99	25.87	33,384.70	3.21	3,376	1.99	70.76
Laurus Labs	1,542.30	83,262.08	92.55	6,867.80	#1 22.01	890	21.18	71.63

Automatic Screeners on ScanX

Day 1 Unusual Volume

Resistance 1 Breached

Growth Rate

Revenue Growth

2.24 %

Net Income Growth

-26.86 %

Cash Flow Change

-21.28 %

ROE

-33.71 %

ROCE

-31.02 %

EBITDA Margin (Avg.)

-17.18 %

Corporate Action

Record Date	Corporate Action	Information	Announcement Day	LTP at Annoucement	LTP at Record Day
23 Jul 2026	Quarterly Result Announcement	NA	23 Jul 2026	1,433.10	1,458.20
11 Aug 2021	Dividend	₹ 5.00 /share	09 Aug 2021	898.60	912.60
10 Aug 2022	Dividend	₹ 5.00 /share	08 Aug 2022	937.55	1,029.55
26 Aug 2022	Annual General Meeting	NA	26 Aug 2022	955.10	1,025.45
21 Jul 2023	Dividend	₹ 8.50 /share	21 Jul 2023	943.95	1,056.20
02 Aug 2024	Dividend	₹ 13.00 /share	02 Aug 2024	1,358.80	1,546.15
20 Aug 2024	Annual General Meeting	NA	20 Aug 2024	1,358.80	1,575.50
29 Oct 2024	Quarterly Result Announcement	NA	29 Oct 2024	1,654.10	1,503.50
28 Jan 2025	Quarterly Result Announcement	NA	28 Jan 2025	1,510.25	1,395.90
13 May 2025	Quarterly Result Announcement	NA	13 May 2025	1,415.25	1,511.60
27 Jun 2025	Dividend	₹ 13.00 /share	27 Jun 2025	1,511.60	1,512.75
27 Jun 2025	Dividend	₹ 3.00 /share	27 Jun 2025	1,511.60	1,512.75
16 Jul 2025	Annual General Meeting	NA	16 Jul 2025	1,511.60	1,490.90
25 Jul 2025	Quarterly Result Announcement	NA	25 Jul 2025	1,505.30	1,487.25
30 Oct 2025	Quarterly Result Announcement	NA	30 Oct 2025	1,527.10	1,581.10
23 Jan 2026	Quarterly Result Announcement	NA	23 Jan 2026	1,512.50	1,370.40
13 May 2026	Quarterly Result Announcement	NA	13 May 2026	1,223.05	1,292.30
05 Jun 2026	Dividend	₹ 13.00 /share	05 Jun 2026	1,292.30	1,398.70
25 Jun 2026	Annual General Meeting	NA	25 Jun 2026	1,292.30	1,437.90

Funding House	Current Holding %	1M Change	1M Change %	3M Change %
Franklin India Multi Asset Allocation Fund Direct-Growth	1.48%	77926	0.45%	0.43%
Groww Multi Asset Allocation Fund Direct-Growth	0.00%	-31509	-1.02%	0.00%
JioBlackRock Arbitrage Fund Direct-Growth	0.59%	17250	0.45%	0.59%
Unifi Dynamic Asset Allocation Fund Direct-Growth	0.19%	17000	0.19%	0.19%
Helios Arbitrage Fund Direct-Growth	1.06%	10875	1.06%	1.06%
The Wealth Company Small Cap Fund Direct-Growth	0.00%	-5000	-1.23%	-3.19%
The Wealth Company Multi Asset Allocation Fund Direct-Growth	0.91%	-3500	-0.29%	-0.16%
The Wealth Company Arbitrage Fund Direct-Growth	0.00%	-3000	-0.25%	-0.24%
Old Bridge Arbitrage Fund Direct-Growth	0.00%	-2625	-0.22%	0.00%
Parag Parikh Large Cap Fund Direct-Growth	0.59%	1913	0.05%	0.05%
JioBlackRock Sector Rotation Fund Direct-Growth	0.59%	773	0.08%	0.05%
DSP Nifty Healthcare Index Fund Direct-Growth	7.56%	636	0.27%	0.42%
JioBlackRock Nifty 50 Index Fund Direct-Growth	0.73%	584	0.06%	0.06%
Zerodha Nifty 50 Index Fund Direct-Growth	0.73%	280	0.06%	0.06%
UTI Nifty500 Shariah Index Fund Direct-Growth	1.38%	198	0.06%	0.05%
SBI Nifty100 Low Volatility 30 Index Fund Direct-Growth	3.71%	-153	0.26%	0.25%
Nippon India Nifty India Manufacturing Index Fund Direct-Growth	1.98%	-134	0.08%	0.02%
Axis BSE India Sector Leaders Index Fund Direct-Growth	1.03%	-113	0.08%	0.06%
HDFC BSE India Sector Leaders Index Fund Direct-Growth	1.03%	-82	0.08%	0.05%
Nippon India BSE Sensex Next 30 Index Fund Direct-Growth	3.06%	79	0.15%	0.10%
Bandhan BSE India Sector Leaders Index Fund Direct-Growth	1.04%	-73	0.09%	0.06%
Angel One Nifty 50 Index Fund Direct-Growth	0.73%	52	0.06%	0.06%
Groww Nifty 50 Index Fund Direct-Growth	0.73%	50	0.06%	0.06%
Choice Nifty 50 Index Fund Direct-Growth	0.73%	32	0.06%	0.73%
Zerodha Nifty LargeMidcap250 Plus 8-13 Yr G-Sec 70:30 Index Fund Direct-Growth	0.15%	24	-0.04%	0.15%

Technical Indicators

RSI(14)

Neutral

66.34

ATR(14)

Less Volatile

29.52

STOCH(9,6)

Neutral

79.25

STOCH RSI(14)

Overbought

91.37

MACD(12,26)

Bullish

6.36

ADX(14)

Strong Trend

25.91

UO(9)

Bearish

41.60

ROC(12)

Uptrend And Accelerating

5.41

WillR(14)

Neutral

-22.89

About Cipla

Cipla Ltd is a leading Indian pharmaceutical company that manufactures, develops, and markets a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company operates in two segments: Pharmaceuticals and New ventures. Its product portfolio includes complex generics and drugs in respiratory, anti-retroviral, urology, cardiology, anti-infective,...more

Website

https://www.cipla.com

Chairperson NameY K Hamied

About Scanx

We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.

Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation.
We plan to change that - a technology-led and artificial intelligence enabled platform built for super traders and long term investors.

Disclaimer:

The data and information provided on this website is for general informational and research purposes only. While we strive to ensure that the content is accurate, up-to-date, and reliable, this platform utilizes artificial intelligence (AI) tools to generate, curate, and summarize information. As such, the content may occasionally contain errors, omissions, or outdated information. All users are therefore advised to cross verify the source of the data and information.
This website does not constitute professional, legal, financial, medical, or any other form of licensed advice. Users are encouraged to independently verify any information before relying on it, especially for decisions that may have legal, financial, or personal consequences.
The views, analyses, and summaries presented on this platform may be generated or assisted by AI and do not necessarily reflect the opinions of the website owners, operators, editors, or affiliates.
We make no warranties or representations, express or implied, regarding the completeness, accuracy, reliability, suitability, or availability of the information contained on this website. Any reliance you place on such information is strictly at your own risk.
This website may include links to third-party sources or content. We do not control or endorse the nature, accuracy, or availability of those external sites and are not responsible for any content or damages arising from their use.
By using this website, you acknowledge and agree that the use of AI-generated content involves inherent limitations, uncertainties and inaccuracies, and you accept full responsibility for how you interpret and use the information provided.
We reserve the right to modify, update, or remove content and this disclaimer at any time without prior notice.

Part of Raise Financial Services

SEBI Stock Broker Registration No: INZ000006031 | Depository Participant (CDSL) ID: IN-DP-289-2016 | SEBI Research Analyst Registration No: INH000023357 Exchange Membership No. : NSE: 90133 | BSE: 6593 | MCX: 56320

Registered Office: Unit No. 2201, 22nd Floor, Gold Medal Avenue, S.V. Road, Beside Patel Petrol Pump, Piramal Nagar, Goregaon West, Mumbai - 400104

Cipla

Company News

Peer Comparison Compare Peers on Screener

Automatic Screeners on ScanX

Corporate Action

Mutual Fund Holdings

Technical Indicators

About Cipla